This infographic, with data featured in amfAR’s PEPFAR Pulse study, examines the percentage change in PEPFAR prevention expenditures from FY24 to FY25. Significant challenges persist in the wake of cuts to PEPFAR programs, as the ripple effects continue to be felt across the field and organizations grapple with how to maintain services with fewer resources.
Percentage Change in PEPFAR Prevention Expenditures, FY24 to FY25
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
People’s Research Agenda 2025 Update Summary Table
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations. View this summary table or see the full report and dashboard.
Alimatravir (AMI) Licensing Timeline
This timeline demonstrates the speed of generic licensing for alimatravir (AMI) compared to lenacapavir (LEN) and cabotegravir (CAB).
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible
The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.
INCLUSION Global Study Details
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries. For more details on all ongoing LEN implementation studies, see our map and visit the integrated study dashboard.
Long-Acting PrEP Generic License Coverage
This map shows country coverage under current voluntary licensing agreements for generic versions of three long-acting PrEP products: alimatravir (AMI), cabotegravir (CAB) and lenacapavir (LEN). The graphic reflects publicly announced licenses and does not indicate product registration, availability or access within countries. For more information, visit the PrEPWatch Long-Acting PrEP Status page.
Lenacapavir Implementation Studies
Ongoing and planned implementation studies for the lenacapavir as of July 2026. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Potential Lenacapavir Supply, 2026-28
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.